article thumbnail

Managing Opportunities and Risks in Generative AI Use for Clinical Research

PPD

Generative artificial intelligence (AI) has captured global attention for its transformative potential across industries, and nowhere is the promise greater — or more fraught — than in health care and clinical research. These domains are ripe for innovation. But the stakes are uniquely high.

article thumbnail

The AI model that is changing clinical trial design

Drug Target Review

Chief Executive Officer Steve Herne has spent more than 25 years in clinical research, with senior roles at WCG, Bioclinica and Covance. We take transparency seriously, documenting every aspect of our models – from how they are trained to how they are validated in their specific context of use.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How FSP Solutions Support Risk-Based Methodologies and Tech Innovation in Clinical Operations

PPD

In the past, these developers mostly used in-house resources for their clinical monitoring and site management capabilities, whereas today they often prefer functional service provider (FSP) or full-service outsourcing (FSO) models, or a hybrid of the two, to ensure on-time and on-budget delivery of clinical operations.

article thumbnail

2025: Perspectives and Predictions From Advarra Thought Leaders

Advarra

2024 has been a year of growth and evolution in clinical research. These topics include perspectives on how artificial intelligence (AI) will be leveraged in clinical research, key regulatory trends shaping the industry, the movements of site consolidation, the continued challenges (and potential solutions) of study startup, and more.

article thumbnail

Are you prepared for ICH E6 (R3)?  

Advarra

10 areas that may impact your organization The third revision (R3) of the ICH E6 Guideline for Good Clinical Practice represents a significant modernization of global clinical research standards. Patient consent: Do your consent documents meet patients’ language and literacy needs across media formats (text, visuals, video)?

article thumbnail

The Real Cost of Complexity: What Every Drug Developer Needs to Know

PPD

The drug development industry faces rising costs and increasingly complex protocols as top challenges, with 49% of developers citing costs as their primary concern and 39% pointing to protocol complexity as a key hurdle, according to a recent survey of 150 drug developers worldwide by the PPD clinical research business of Thermo Fisher Scientific.

article thumbnail

How FSP Models Help Biotech Companies Augment Their Clinical Development Needs

PPD

FSP solutions are being more frequently utilized by biotech companies Biotech companies employ contract research organizations (CROs) to handle trial-related functions and services, often delivered through a full-service outsourcing (FSO) model, an FSP model or a mixed model combining both. FSP outsourcing is growing faster than FSO.